Arterial hypertension and coronary heart disease, hypertensive heart disease and foreplasma

被引:0
作者
Eckert, S. [1 ]
机构
[1] Uniyersitatsklin Ruhr Univ Bochum, Herz & Diabetes Zentrum Nordrhein Westfalen, Georgstr 11, D-32545 Bad Oeynhausen, Germany
来源
JOURNAL FUR HYPERTONIE | 2006年 / 10卷 / 03期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Arterial hypertension is an independent cardiovascular risk factor for the development of vascular stenoses in the cerebral, peripheral and coronary flow paths. In the heart, an increase in pressure in the left ventricle and atria frequently causes left-ventricular hypertrophy and dilatation of the left atrium. The size of the left atrium, potentially frequent blood pressure peaks and increasing fibrosis predispose patients to atrial fibrillation. At the vascular level, arterial hypertension favors the development of atherosclerosis of the epicardial vessels with coronary stenoses (coronary artery disease) and of the coronary micro-flow path via a media thickening (endothelial dysfunction). Diastolic and systolic heart insufficiency, as well as atrial size and wall thickness, can all be diagnosed using echocardiography. Echocardiography should be performed on first diagnosis of arterial hypertension and at regular intervals thereafter. Adequate blood pressure adjustment can improve endothelial dysfunction, in some cases even stop it. In the long term, with specific treatment of additional risk factors, it can help to stop or delay the development of coronary and hypertensive heart disease, as well as to reduce atrial fibrillation.
引用
收藏
页码:18 / 23
页数:6
相关论文
共 49 条
[1]   Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults - The strong heart study [J].
Bella, JN ;
Palmieri, V ;
Roman, MJ ;
Liu, JE ;
Welty, TK ;
Lee, ET ;
Fabsitz, RR ;
Howard, BV ;
Devereux, RB .
CIRCULATION, 2002, 105 (16) :1928-1933
[2]   Is atrial fibrillation an inflammatory disorder? [J].
Boos, CJ ;
Anderson, RA ;
Lip, GYH .
EUROPEAN HEART JOURNAL, 2006, 27 (02) :136-149
[3]   ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography) [J].
Cheitlin, MD ;
Armstrong, WF ;
Aurigemma, GP ;
Beller, GA ;
Bierman, FZ ;
Davis, JL ;
Douglas, PS ;
Faxon, DP ;
Gillam, LD ;
Kimball, TR ;
Kussmaul, WG ;
Pearlman, AS ;
Philbrick, JT ;
Rakowski, H ;
Thys, DM ;
Antman, EM ;
Smith, SC ;
Alpert, JS ;
Gregoratos, G ;
Anderson, JL ;
Hiratzka, LF ;
Faxon, DP ;
Hunt, SA ;
Fuster, V ;
Jacobs, AK ;
Gibbons, RJ ;
Russell, RO .
CIRCULATION, 2003, 108 (09) :1146-1162
[4]  
Chen ZM, 2005, LANCET, V366, P1622
[5]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[6]   Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy [J].
Dahlof, B ;
Zanchetti, A ;
Diez, J ;
Nicholls, MG ;
Yu, CM ;
Barrios, V ;
Aurup, P ;
Smith, RD ;
Johansson, M .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1855-1864
[7]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906
[8]  
Deutsche Hochdruckliga, 2005, NIEREN HOCHDRUCK, V34, P481
[9]  
Devereux RB, 2002, J HYPERTENS, V20, pS5
[10]   Progressive hypertrophy regression with sustained pressure reduction in hypertension:: the Losartan Intervention For Endpoint Reduction study [J].
Devereux, RB ;
Palmieri, V ;
Liu, JE ;
Wachtell, K ;
Bella, JN ;
Boman, K ;
Gerdts, E ;
Nieminen, MS ;
Papademetriou, V ;
Dahlöf, B .
JOURNAL OF HYPERTENSION, 2002, 20 (07) :1445-1450